Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.
Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K, O'Brien NA, Roxanis I, Li JL, Bridge E, Finn R, Siamon D, McGowan P, Duffy MJ, O'Donovan N, Crown J, Kong A.
Canonici A, et al.
Oncotarget. 2013 Oct;4(10):1592-605. doi: 10.18632/oncotarget.1148.
Oncotarget. 2013.
PMID: 24009064
Free PMC article.